Anne Ghys

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

James C. Sullivan, Sandra De Meyer, Doug J. Bartels et al. · Clinical Infectious Diseases · 2013 · 164 citations · Full text

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels et al. · PLoS ONE · 2012 · 87 citations · Full text

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial

Sandra De Meyer, Inge Dierynck, Anne Ghys et al. · Hepatology · 2012 · 43 citations

Deep-Sequencing Analysis of the Gene Encoding the Hepatitis C Virus Nonstructural 3–4A Protease Confirms a Low Prevalence of Telaprevir-Resistant Variants at Baseline and the End of the REALIZE Study

Inge Dierynck, Kim Thys, Anne Ghys et al. · The Journal of Infectious Diseases · 2014 · 20 citations

An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi <i>m</i> e HCV RNA Assay

Christoph Sarrazin, Inge Dierynck, Gavin Cloherty et al. · Journal of Clinical Microbiology · 2015 · 15 citations · Full text